The Latest Cardiac and Vascular News
New Cardiac Unit Supports Innovative New Procedures, Including Pulsed Field Ablation for Heart Rhythm Disorders PITTSBURGH, June 18, 2026 /PRNewswire/ — Allegheny Health Network’s (AHN) Allegheny General Hospital (AGH) today announced completion of a $19 million renovation and expansion…
CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software, which received U.S. Food and Drug Administration clearance in 2024 for predicting the one-year risk of atrial fibrillation or flutter (AF). The study, titled “Multi-Center Validation of an Artificial Intelligence-Enabled ECG Model to Predict 1-Year Risk of Atrial Fibrillation or Fl
Investments in intracardiac echocardiography (ICE) technologies highlight Medtronic’s commitment to driving durable growth in the cardiac ablation business through a differentiated portfolio of technologies GALWAY, Ireland, June 3, 2026 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global…
NEW YORK–(BUSINESS WIRE)– #BetterOutcomes–AccurKardia, Inc., an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced that it has been granted US Patent No. 12,620,488 for the company’s proprietary machine-learning-based system for identifying cardiac amyloidosis from a standard, routinely performed 12-lead ECG. Cardiac amyloidosis is a serious, often fatal heart disease in which abnormal proteins build up in heart tissue, causing the heart muscle to stiffen and even
LAGUNA HILLS, Calif.–(BUSINESS WIRE)—- $ADGM #ARRHYTHMIA–Adagio Medical Holdings, Inc (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the submission of its Premarket Approval (“PMA”) application to the U.S. Food and Drug Administration (“FDA”) for the vCLAS Ventricular Ablation System for the treatment of drug-refractory, recurrent, sustained monomorphic ventricular tachycardia (“VT”) in patients with isch
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic
World’s Leading Provider of Cutting-Edge Smart Ring Solutions NEW YORK, May 10, 2026 /PRNewswire/ — RingConn opened Gen 3 pre-orders on May 5th ahead of its official May 29th launch, marking the occasion with a feature on the iconic One Times Square billboard in New York City on the…
NEW YORK–(BUSINESS WIRE)– #Cardiology–AccurKardia, an innovator in ECG-based diagnostics technology, today announced that AK+ Guard™ has been selected as winner of the “Best New ECG Technology Solution” award in the 10th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies and products in the global digital health and medical technology market. AI-powered AK+ Guard hyperkale
WHITE PLAINS, N.Y., May 1, 2026 /PRNewswire/ — Retia Medical today announced the first public presentation of results from its non-invasive cardiac output algorithm, which estimates cardiac output using signals from sensors already placed on patients as standard of care: a pulse oximeter…
LAGUNA HILLS, Calif.–(BUSINESS WIRE)—- $ADGM #Arrhythmia–Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today reported six month results from its FULCRUM-VT Investigational Device Exemption (“IDE”) clinical trial, which will be used to support the Company’s application for Food and Drug Administration (“FDA”) Premarket Approval of the vCLAS Ventricular Ablation System. The results were prese
